Emergent BioSolutions Initiates Final Pivotal Study to Support Licensure of BioThrax at Large Scale
Emergent BioSolutions Inc. (NYSE:EBS) today announced the initiation of the pivotal non-clinical efficacy study to demonstrate that BioThrax® (Anthrax Vaccine Adsorbed) manufactured at large scale...
Emergent BioSolutions Awarded Contract to Develop a Dry Formulation of NuThrax, a Next Generation Anthrax Vaccine
Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has signed a contract with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health...
Emergent BioSolutions and MorphoSys Sign License Agreement to Co-Develop and Commercialize Prostate Cancer Drug Candidate ES414
Emergent BioSolutions Inc. (NYSE: EBS) and MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX, OTC: MPSYY) today announced an agreement for the joint development and commercialization of...
U.S. Government Exercises Contract Options Valued at $18.9M for Emergent BioSolutions’ Vaccinia Immune Globulin Intravenous Program
Emergent BioSolutions Inc. (NYSE:EBS) announced today that the Centers for Disease Control and Prevention (CDC) has exercised options under contract 200-2012-52242 for the supply of Vaccinia Immune...
Emergent BioSolutions Submits Biologics License Application to FDA for Anthrax Immune Globulin Intravenous (Human)
Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has submitted a Biologics License Application to the U.S. Food and Drug Administration (FDA) for Anthrax Immune Globulin Intravenous...
Emergent BioSolutions Reports Financial Results for Second Quarter and First Six Months of 2014
Emergent BioSolutions Inc. (NYSE: EBS) reported total revenue for Q2 2014 of $110.3 million as compared to $82.4 million in 2013. Total revenues for the first six months of 2014 were $164.2 million...
Emergent BioSolutions to Release Second Quarter 2014 Financial Results and Conduct a Conference Call on August 7, 2014
Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call at 5:00 pm (Eastern Time) on Thursday, August 7, 2014. Company management will discuss the financial results for the second quarter...
Emergent BioSolutions to Participate in June 2014 Investor Conferences
Emergent BioSolutions Inc. (NYSE: EBS) announced today that a member of the company’s senior management team will participate in the following investor conferences in June...
Emergent BioSolutions to Hold Annual Meeting of Stockholders Thursday May 22, 2014 at 9:00 AM Eastern; Webcast Will Be Available
Emergent BioSolutions Inc. (NYSE: EBS) has announced that it will hold its Annual Meeting of Stockholders on Thursday, May 22, 2014 beginning at 9:00 AM Eastern at the Sheraton Rockville Hotel, 920...
Emergent BioSolutions Reports First Quarter 2014 Financial Results
May 8, 2014-- Emergent BioSolutions Inc. (NYSE: EBS) reported total revenue for Q1 2014 of $53.9 million as compared to $43.1 million in 2013. In addition, Q1 2014 net loss was $20.2 million, or...
Emergent BioSolutions to Release First Quarter 2014 Financial Results and Conduct a Conference Call on May 8, 2014
Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call at 5:00 pm (Eastern Time) on Thursday, May 8,...
Emergent BioSolutions and FDA Finalize Comparability Protocols Enabling Manufacturing of BioThrax Consistency Lots in Building 55
Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has initiated manufacturing of BioThrax® (Anthrax Vaccine Adsorbed) consistency lots in Building 55, following review by the U.S. Food...